The stock of AxoGen, Inc. (NASDAQ:AXGN) is a huge mover today! The stock decreased 6.40% or $0.55 during the last trading session, hitting $8.05. About 446,083 shares traded hands or 141.42% up from the average. AxoGen, Inc. (NASDAQ:AXGN) has risen 63.81% since April 4, 2016 and is uptrending. It has outperformed by 62.72% the S&P500.
The move comes after 5 months negative chart setup for the $282.92 million company. It was reported on Nov, 4 by Barchart.com. We have $7.08 PT which if reached, will make NASDAQ:AXGN worth $33.95 million less.
AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage
Out of 2 analysts covering AxoGen (NASDAQ:AXGN), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. AxoGen has been the topic of 5 analyst reports since August 11, 2015 according to StockzIntelligence Inc. As per Tuesday, August 11, the company rating was upgraded by Zacks. The rating was maintained by Wedbush on Friday, August 28 with “Outperform”. Lake Street downgraded it to “Hold” rating and $9 target price in Thursday, November 3 report.
According to Zacks Investment Research, “AxoGen Corp. is a regenerative medicine company engaged in the development and commercialization of technologies for peripheral nerve reconstruction and regeneration. It offers products for the repair of peripheral nerve injuries. AxoGen Corp was formerly known as LecTec Corporation.”
More notable recent AxoGen, Inc. (NASDAQ:AXGN) news were published by: Globenewswire.com which released: “AxoGen, Inc. Reports Financial Results for Third Quarter 2016” on November 02, 2016, also Reuters.com with their article: “BRIEF-Axogen Inc says qtrly loss per share $0.08” published on November 02, 2016, Globenewswire.com published: “AxoGen, Inc. Announces the Refinancing of its Debt Facility” on October 26, 2016. More interesting news about AxoGen, Inc. (NASDAQ:AXGN) were released by: Blogs.Wsj.com and their article: “CFO Moves: Delphi Automotive, Hain Celestial Group, AxoGen Inc.” published on March 01, 2016 as well as Globenewswire.com‘s news article titled: “AxoGen, Inc. to Participate at the 28th Annual ROTH Growth Conference” with publication date: March 09, 2016.
AXGN Company Profile
AxoGen, Inc. (AxoGen), incorporated on June 20, 1977, is a medical technology firm focused on peripheral nerve repair. The Firm provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. The Company’s regenerative medicine products include Avance Nerve Graft, a processed nerve allograft for bridging severed nerves without the comorbidities associated with a nerve autograft additional surgical site; AxoGuard Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for repair of severed nerves, and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves. The Firm also sells AxoTouch Two Point Discriminator, a measurement tool for determining innervation density and sensory function.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.